Show simple item record

dc.contributor.authorFinn, David P.
dc.date.accessioned2013-11-01T11:02:42Z
dc.date.available2013-11-01T11:02:42Z
dc.date.issued2012-01
dc.identifier.citationFinn DP, Viveros MP, Marco EM (2012) 'The endocannabinoid system and emotional processing: pathophysiology and therapeutic potential'. Journal Of Psychopharmacology, 26 (1):3-6.en_US
dc.identifier.issn1461-7285
dc.identifier.urihttp://hdl.handle.net/10379/3788
dc.descriptionJournal articleen_US
dc.description.abstractAlthough the pharmacological and medicinal properties of the plant Cannabis sativa have long been known and appreciated, the discovery of the endocannabinoid system began with the isolation of [delta]9-tetrahydrocannabinol (THC), the major psychoactive component of the plant, in the mid-1960s (Gaoni and Mechoulam, 1964). Extensive pharmacological studies followed, and, by the end of the last century, the endogenous cannabinoid (endocannabinoid) system was known to comprise at least two metabotropic receptors, cannabinoid receptor types 1 and 2 (CB1 and CB2); two endogenous ligands, the ethanolamine of arachidonic acid, also known as anandamide (AEA), and 2-arachidonoyl-glycerol (2-AG); and the enzymes responsible for their synthesis and catabolism. However, in the last decade (2000-2010), our understanding of the endocannabinoid system has experienced a true revolution. Novel lipid molecules with endocannabinoid activity have been identified; endocannabinoids have been reported to activate additional targets, including the Transient Receptor Potential Vanilloid 1 (TRPV1) channel, nuclear peroxisome proliferator activated receptors (PPARs) and the G protein-coupled receptor GPR55. Moreover, novel pathways for endocannabinoid synthesis and degradation have been discovered. In this special issue, Pamplona and Takahashi (2012) review the discovery of the endocannabinoid system and present the most recent advances in our understanding of the physiology of this system.en_US
dc.formatapplication/pdfen_US
dc.language.isoenen_US
dc.publisherSAGEen_US
dc.relation.ispartofJournal Of Psychopharmacologyen
dc.subjectAnimalsen_US
dc.subjectCannabinoid Receptor Modulators/metabolismen_US
dc.subjectEmotions/physiologyen_US
dc.subjectEndocannabinoidsen_US
dc.subjectHumansen_US
dc.subjectMental Disorders/drug therapyen_US
dc.subjectMental Disorders/physiopathologyen_US
dc.subjectNeuropsychiatry/methodsen_US
dc.titleThe endocannabinoid system and emotional processing: pathophysiology and therapeutic potential.en_US
dc.typeArticleen_US
dc.date.updated2013-01-09T14:53:05Z
dc.identifier.doi10.1177/0269881111428526
dc.local.publishedsourcehttp://dx.doi.org/10.1177/0269881111428526en_US
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funder|~|
dc.internal.rssid1332097
dc.local.contactDavid Finn, Dept. Of Pharmacology &, Therapeutics, Nui, Galway. 5280 Email: david.finn@nuigalway.ie
dc.local.copyrightcheckedYes
dc.local.versionACCEPTED
nui.item.downloads368


Files in this item

Attribution-NonCommercial-NoDerivs 3.0 Ireland
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

The following license files are associated with this item:

Thumbnail

This item appears in the following Collection(s)

Show simple item record